About US
Contact us
-
Amgen prices bone drug Evenity on par with rival Tymlos, but a tough marketing road lies aheadAmgen is pricing its newly approved osteoporosis drug Evenity on par with Radius Health’s competitor anabolic Tymlos. But its cardiovascular risk has already drawn outcry from a consumer activist gro2019/4/17
-
J&J, under 'accelerating' generic and biosim attack, expects growth to bottom out in 2019Johnson & Johnson's pharma business has been beating the market for years now, but that's about to change. A wave of patent expirations will put a drag on J&J's top-performing unit this year2019/4/16
-
Ionis' Tegsedi gets a U.K. boost after NICE reverses initial guidanceThe path for Ionis’ Tegsedi in the U.K. looked rocky after a preliminary “no” last year from England'sdrug-price watchdog. Fortunately for the drugmaker, that decision was reversed. Tuesday, the Nati2019/4/16
-
AstraZeneca’s Lynparza gets EC approval for breast cancerThe European Commission (EC) has approved AstraZeneca drug Lynparza (olaparib) as a monotherapy to treat locally-advanced or metastatic breast cancer in adults. The drug, which is being co-developed2019/4/15
-
Pfizer to use Concerto HealthAI technology for cancer treatmentsPfizer has partnered with patient-centred research firm Concerto HealthAI to fast-track actionable patient insights for investigational and commercialised cancer therapies. The partnership will lever2019/4/15
-
FDA approves Amgen’s postmenopausal osteoporosis drug EvenityAmgen has received the US Food and Drug Administration (FDA) approval for Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk for fracture. Evenity is a humanised mo2019/4/11
-
Researchers develop new vaccine to teach immune system to attack cancerResearchers at Mount Sinai in the US have developed a new immunotherapy that can be injected directly into a tumour cell and teach a patient’s own immune system to kill cancer throughout the body. Ca2019/4/11
-
England's NICE rebuffs Pfizer and Astellas' Xtandi in nonmetastatic prostate cancerPfizer and Astellas’ Xtandi is looking for a leg up on prostate cancer rival Erleada from J&J. But it won't be getting it in England. In a final appraisalreleasedMonday, the National Institute fo2019/4/10
-
GSK's Dovato chalks up first 2-drug regimen nod for new HIV patients, but will doctors use it?In a landmark win for GlaxoSmithKline’s ViiV Healthcare and its ambition to reduce the number of medications HIV patients are taking—and beat rival Gilead Sciences along the way—the FDA has approved2019/4/10
-
FDA declares 40 generics free of carcinogens as 'sartan' recalls continueAs recalls on blood pressure drugs continue to plague drugmakers, the FDA declareda slate of 40 generic pills safe to use. On Thursday, the agency releaseda listof 40 generic angiotensin II receptor2019/4/9